Pharmaceutical Technology

FEBRUARY 9, 2023

Ibutamoren mesylate is under clinical development by Lumos Pharma and currently in Phase I for Turner Syndrome. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. It is administered orally.

Hormones 100

Hormones Clinical Trials Clinical Trials Genetics 100

ProRelix Research

SEPTEMBER 26, 2023

Endocrine disorders result from the improper functioning of endocrine glands that secrete and regulate hormones responsible for functioning of various organs.

Hormones 52

Hormones Development Regulation Research 52

Pharmaceutical Technology

FEBRUARY 24, 2023

(LAI-287 + semaglutide) is under clinical development by Novo Nordisk and currently in Phase III for Type 2 Diabetes. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Insulin 182

Insulin Hormones Drugs Clinical Trials 182

STAT News

MARCH 21, 2023

A new obesity treatment being developed by Altimmune met goals for weight loss in a mid-stage clinical trial, but the data showed it doesn’t have a leg up on other popular drugs on the market.

Hormones 98

Hormones Drugs Clinical Trials Clinical Trials 98

Drug Discovery World

MAY 6, 2024

The company’s lead therapeutic peptide candidate is currently in a Phase III clinical trial for the treatment of hypoparathyroidism. Hypoparathyroidism is a rare condition defined by a deficiency of parathyroid hormone (PTH) that results in decreased calcium and elevated phosphorus levels in the blood.

Hormones 52

Hormones Clinical Trials Clinical Trials Trials 52

Pharmaceutical Technology

AUGUST 8, 2022

The approval was based on findings from the international, randomised, open-label Phase III DESTINY-Breast04 clinical trial. Furthermore, Enhertu’s safety profile was in line with prior clinical trials without any new safety concerns detected. months compared with 5.1 months for the chemotherapy arm.

FDA Approval 264

FDA Approval HR Clinical Trials Clinical Trials 264

Pharmaceutical Technology

AUGUST 8, 2022

The US Food and Drug Administration (FDA) has granted approval for a supplemental New Drug Application (sNDA) of Orion and its partner Bayer ’s Nubeqa (darolutamide) plus docetaxel to treat metastatic hormone-sensitive prostate cancer (mHSPC) patients.

Hormones 246

Hormones Clinical Trials Clinical Trials Licensing 246

pharmaphorum

DECEMBER 1, 2021

Sanofi said it would also apply its mRNA vaccine platform – acquired along with Translate Bio earlier this year – to find other acne vaccine candidates that could start clinical trials in 2023. The post Sanofi snaps up acne vaccine developer Origimm Bio appeared first on. Photo by Scott Webb on Unsplash.

Vaccination 105

Vaccination Vaccine Development Hormones 105

XTalks

JANUARY 9, 2024

The thyroid plays a critical role in the body by producing hormones that regulate metabolism, heart rate and body temperature among others. Women are five to eight times more likely than men to experience thyroid conditions, with one in eight women likely to develop thyroid issues during their lifetime.

Hormones 105

Hormones Antibody Trials Production 105

Pharmaceutical Technology

JUNE 5, 2023

Rezvilutamide is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Liver Failure (Hepatic Insufficiency). GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Medicine 100

Medicine Hormones Production Clinical Trials 100

Pharmaceutical Technology

JUNE 5, 2023

Rezvilutamide is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Prostate Cancer. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Medicine 100

Medicine Hormones Production Clinical Trials 100

XTalks

SEPTEMBER 2, 2020

Viking Therapeutics is a clinical-stage biopharmaceutical company that develops novel therapies for metabolic and endocrine disorders. VK2809 is a novel, oral small molecule thyroid hormone receptor beta agonist that has selectivity for liver tissue. VK2809 and the VOYAGE Trial.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Insulin 98

Pharmaceutical Technology

JUNE 6, 2023

Ecubectedin is a small molecule commercialized by Pharma Mar, with a leading Phase II program in Hormone Sensitive Breast Cancer. According to Globaldata, it is involved in 5 clinical trials, which are ongoing. Pharma Mar Overview Pharma Mar discovers, develops and markets marine-derived drugs to treat cancer.

Hormones 100

Hormones In-Vitro Genotype Bacteria 100

Pharmaceutical Technology

MAY 31, 2023

Sym-021 is under clinical development by Les Laboratoires Servier and currently in Phase I for Solid Tumor. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Generic Drugs 100

Generic Drugs Hormones Manufacturing Development 100

Drug Discovery World

FEBRUARY 20, 2024

Edinburgh-based PhaSER Biomedical (PhaSER) has received a Bill & Melinda Gates Foundation grant totalling $2.3m The three-year programme will make the PhaSER technology a collaborating institution within the Global Health Discovery Collaboratory Programme, which is funded by the Gates Foundation. A key stage of compound progression.

Drugs 52

Drugs In-Vivo Hormones Development 52

Pharmaceutical Technology

FEBRUARY 27, 2023

The regulatory approval is based on the data obtained from the multi-centre, double-blind, placebo-controlled, randomised Phase III ARASENS clinical trial. The trial assessed the safety and efficacy of oral darolutamide plus ADT and chemotherapy docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC) patients.

Hormones 130

Hormones Trials Clinical Trials Clinical Trials 130

Pharmaceutical Technology

FEBRUARY 27, 2023

Enzalutamide is under clinical development by Pfizer and currently in Phase I for Relapsed Multiple Myeloma. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. EU and Asia. EU and Asia.

Hormones 113

Hormones Contract Manufacturing Manufacturing Development 113

Pharmaceutical Technology

FEBRUARY 24, 2023

(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Genital Warts (Condylomata Acuminata). GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Contract Manufacturing 100

Contract Manufacturing Dermatology Hormones Production 100

Pharmaceutical Technology

FEBRUARY 24, 2023

(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Cervical Intraepithelial Neoplasia (CIN). GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Contract Manufacturing 100

Contract Manufacturing Dermatology Hormones Production 100

Pharmaceutical Technology

FEBRUARY 23, 2023

Buparlisib hydrochloride is under clinical development by Adlai Nortye Biopharma and currently in Phase II for Mantle Cell Lymphoma. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Hormones 130

Hormones Development Drugs Clinical Trials 130

Pharmaceutical Technology

FEBRUARY 27, 2023

Enzalutamide is under clinical development by Pfizer and currently in Phase I for Myelofibrosis. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. EU and Asia. EU and Asia.

Hormones 100

Hormones Contract Manufacturing Manufacturing Development 100

Pharmaceutical Technology

FEBRUARY 27, 2023

Enzalutamide is under clinical development by Pfizer and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL). GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. EU and Asia. EU and Asia.

Hormones 100

Hormones Contract Manufacturing Manufacturing Development 100

pharmaphorum

OCTOBER 17, 2022

Bayer has added another clinical trial to its extensive phase 3 programme for oral neurokinin antagonist elinzanetant, hoping to show that it can treat vasomotor symptoms (VMS) in breast cancer patients. There are around 2.3

Trials 111

Trials Hormones Clinical Trials Clinical Trials 111

pharmaphorum

AUGUST 30, 2022

Neurocrine Biosciences has featured on lists of potential takeover candidates for years, but has now taken the lead on a buyout of UK biotech Diurnal that if consummated will extend its therapeutic focus further into hormonal disorders. billion this year, giving it plenty of financial muscle for business development.

Hormones 105

Hormones Sales Clinical Trials Clinical Trials 105

pharmaphorum

MAY 27, 2021

billion collaboration to develop the drug in women’s health and oncology in late 2020, including $650 million upfront and $200 million for regulatory milestones. Combining it with the hormonal drugs reduces side effects – such as bone loss – that can result from reducing oestrogen levels.

Hormones 98

Hormones Sales Marketing Drugs 98

XTalks

FEBRUARY 21, 2024

Tirzepatide’s mechanism of action involves activating two naturally produced hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Clinical Trials for MASH Treatment The tirzepatide trial involved approximately 190 adults with MASH at different stages.

Clinical Trials 59

Clinical Trials Clinical Trials Trials Insulin 59

Drug Discovery World

DECEMBER 9, 2022

A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major Phase III clinical trial. . The drug capivasertib combined with hormone therapy doubled the time it took for cancer to progress in people with advanced forms of the most common type of breast cancer. .

Trials 52

Trials Hormones Drugs Genetics 52

Drug Discovery World

DECEMBER 22, 2022

The drug was developed under the leadership of the German Cancer Research Center (DKFZ) in collaboration with Heidelberg University Hospital and Heidelberg University. . The approval is limited to patients who had previously received chemotherapy and who do not respond to hormone withdrawal. .

Drugs 52

Drugs Clinical Trials Clinical Trials Hormones 52

Pharmaceutical Technology

JULY 25, 2022

Being co-developed and co-marketed by AstraZeneca, along with Daiichi Sankyo, Enhertu is a HER2-directed ADC. According to the findings, the ADC offered clinically meaningful efficacy in progression-free survival (PFS) and overall survival (OS) in trial subjects compared to standard of care chemotherapy of physician’s choice.

HR 130

HR Hormones Clinical Trials Clinical Trials 130

pharmaphorum

FEBRUARY 18, 2022

Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up from an earlier estimate of €1 billion, after reviewing new data for the drug in metastatic hormone-sensitive tumours.

Sales 98

Sales Drugs Hormones Pharma Production 98

The Pharma Data

AUGUST 28, 2020

A new breast cancer drug, called TTC-352, can halt the spread of the disease and is safe according to a Phase 1 clinical trial. The drug is being developed and tested by researchers at the University of Illinois at Chicago and is a type of hormone therapy, which targets oestrogen receptor-positive types of breast cancer.

Hormones 52

Hormones Trials Drugs Pharmacy 52

The Pharma Data

JULY 22, 2021

NYSE: PFE) today announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The companies will equally share worldwide development costs, commercialization expenses, and profits. Chief Executive Officer at Arvinas.

Protein 52

Protein Development HR Hormones 52

Pharmaceutical Technology

FEBRUARY 18, 2023

According to Globaldata, it is involved in 24 clinical trials, of which 19 were completed, 2 are ongoing, 1 is planned, and 2 were terminated. The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. The drug candidate is administered orally.

Hormones 100

Hormones Production Development Clinical Trials 100

Drug Discovery World

APRIL 10, 2024

Recent advancements in obesity treatments, exemplified by the approvals of semaglutide and tirzepatide, have spotlighted the field for healthcare providers and developers. Deirdre Albertson , Vice President, Project Management, Cardiovascular/Metabolic Division, ICON, Jack L.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Hormones 52

Drug Discovery World

DECEMBER 19, 2023

Despite VMS, or hot flushes, being a common symptom of menopause, until now, hormone replacement therapy (HRT) was the only treatment. Marci English, Vice President, Head of BioPharma Development, Astellas, added: “Fezolinetant’s novel mechanism of action targets the root cause of moderate to severe VMS associated with menopause.

Hormones 59

Hormones Clinical Trials Clinical Trials Medicine 59

pharmaphorum

FEBRUARY 1, 2021

Kesimpta (ofatumumab) started life as an oncology drug and was first developed by Genmab and licensed to GlaxoSmithKline who marketed under the brand name Arzerra to treat chronic lymphocytic leukaemia.

Drugs 98

Drugs Hormones FDA Approval Clinical Trials 98

XTalks

FEBRUARY 6, 2023

CKD is estimated to affect around 700 million people in the world, and about one in seven patients also develop anemia, a complication of CKD. Poor clinical outcomes can result if anemia of CKD is untreated or undertreated, and this burdens patients and healthcare systems. How Does Jesduvroq ( daprodustat) Work?

FDA Approval 97

FDA Approval Clinical Trials Clinical Trials Trials 97